For the quarter ending 2025-09-30, GNPX had -$243,529 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,799,239 | -8,639,503 |
| Depreciation | 0 | 0 |
| Share-based compensation-Excluding Eloc Purchase Agreement | 385,106 | 274,146 |
| Share-based compensation-The2025Eloc Facility | 89,996 | 365,553 |
| Prepaid expenses and other | -97,553 | 233,531 |
| Research and development supplies | 76,072 | -275,518 |
| Accounts payable | 688,634 | -143,484 |
| Other current liabilities | -573,256 | 75,641 |
| Net cash used in operating activities | -3,187,278 | -8,025,660 |
| Disposals of property and equipment | 0 | 0 |
| Reductions to intellectual property | 0 | 0 |
| Net cash provided by investing activities | 0 | 0 |
| Net proceeds from issuances of common stock, pre-funded warrants, and warrants | 2,943,749 | 7,770,844 |
| Net cash provided by financing activities | 2,943,749 | 7,770,844 |
| Net decrease in cash and cash equivalents | -243,529 | -254,816 |
| Cash and cash equivalents at beginning of period | 1,601,660 | - |
| Cash and cash equivalents at end of period | 1,103,315 | - |
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)